Log in or Sign up for Free to view tailored content for your specialty!
Steatohepatitis/Metabolic Liver Disease News
GLP-1RAs confer ‘metabolic benefit,’ lower odds for MASLD after liver transplantation
SAN DIEGO — Patients with diabetes who were prescribed glucagon-like peptide-1 receptor agonists had lower odds of metabolic dysfunction-associated steatotic liver disease after liver transplantation, noted a presenter at The Liver Meeting.
Monthly efimosfermin offers ‘rapid, meaningful’ improvement for MASH, related fibrosis
SAN DIEGO — Patients treated with once-monthly efimosfermin 300 mg achieved significant improvements in metabolic dysfunction-associated steatohepatitis resolution and fibrosis at 24 weeks, according to late-breaking data.
Liver stiffness measurements may ‘personalize’ HCC risk, surveillance needs in MASLD
SAN DIEGO — Liver stiffness measurements may help predict the risk for hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease, as well as identify those in need of surveillance, according to data.
Log in or Sign up for Free to view tailored content for your specialty!
Novel farnesoid X receptor agonist safe, reduces liver fat content by up to 22.8% in MASH
SAN DIEGO — Once-daily FXR314 was well-tolerated and safely improved liver fat content and biochemical markers over 16 weeks in patients with metabolic dysfunction-associated steatohepatitis, according to research at The Liver Meeting.
GLP-1RAs may offer ‘hepatoprotective’ benefit for diabetes, alcohol-related liver disease
SAN DIEGO — Glucagon-like peptide-1 receptor agonists may help alleviate risk for adverse liver outcomes, particularly hepatic decompensation, among patients with type 2 diabetes and alcohol-associated liver disease.
VIDEO: ‘What you can do now’ for patients with MASLD
PHILADELPHIA — In this video, Nancy S. Reau, MD, FAASLD, AGAF, provides an overview of her postgraduate course presentation at the ACG Annual Scientific Meeting.
VIDEO: Better rates of fibrosis reversal in MASH with Rezdiffra 100 mg, data show
PHILADELPHIA — In this video, Paul Kwo, MD, professor of medicine and director of hepatology at Stanford University, discusses data from the ongoing MAESTRO-NASH trial, which were presented at the ACG Annual Scientific Meeting.
Denifanstat a ‘promising oral therapy’ for the treatment of MASH, related fibrosis
Patients treated with denifanstat 50 mg vs. placebo achieved significant improvements in metabolic dysfunction-associated steatohepatitis resolution and fibrosis, according to study results in The Lancet Gastroenterology & Hepatology.
Multiparametric MRI liver biomarkers predict those ‘likely to achieve’ MASH resolution
Changes in MRI-derived markers of iron-corrected T1 mapping and liver fat content appear effective at predicting histological response among patients treated for metabolic dysfunction-associated steatohepatitis, according to researchers.
Hispanic, Asian populations in US at highest risk for alcohol-associated liver disease
Significant differences in alcohol use, alcohol-related mortality and liver transplant rate by race and ethnicity underscore the need for “tailored approaches to managing” alcohol-related liver disease in the U.S., according to a researcher.
-
Headline News
Q&A: ‘We have to be worried’ about decline in measles vaccination
November 19, 20244 min read -
Headline News
Physicians encouraged to ‘embrace’ technology in practice management
November 19, 20245 min read -
Headline News
Artificial neural network has ‘excellent’ performance in predicting COPD exacerbations
November 20, 20242 min read
-
Headline News
Q&A: ‘We have to be worried’ about decline in measles vaccination
November 19, 20244 min read -
Headline News
Physicians encouraged to ‘embrace’ technology in practice management
November 19, 20245 min read -
Headline News
Artificial neural network has ‘excellent’ performance in predicting COPD exacerbations
November 20, 20242 min read